• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PH-ILD检测工具:外部验证及在ILD患者中的应用

The PH-ILD Detection tool: External validation and use in patients with ILD.

作者信息

Parikh Raj, O'Sullivan David M, Farber Harrison W

机构信息

Division of Pulmonary, Critical Care and Sleep, Hartford Hospital Hartford Connecticut USA.

Department of Research Administration Hartford HealthCare Hartford Connecticut USA.

出版信息

Pulm Circ. 2023 Aug 8;13(3):e12273. doi: 10.1002/pul2.12273. eCollection 2023 Jul.

DOI:10.1002/pul2.12273
PMID:37564922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10410234/
Abstract

Pulmonary hypertension (PH) results in increased morbidity and mortality in patients with interstitial lung disease (ILD). Early recognition of PH in this population is essential for planning diagnostic testing, initiating therapy, and evaluating for lung transplantation. The previously developed PH-ILD Detection tool has significant potential in the evaluation and treatment of ILD patients; the aim of this study was to validate the tool in an independent, multicenter cohort of patients. We conducted a retrospective review of prospectively collected data from 161 ILD patients. Patients were stratified into low- ( = 78, 48.4%), intermediate- ( = 54, 33.5%), and high-risk ( = 29, 18.0%) groups based on the score obtained with the tool. Intermediate- and high-risk patients underwent follow-up echocardiogram (TTE); 49.4% ( = 41) had an abnormal TTE suggestive of underlying PH. These patients underwent right heart catheterization; PH-ILD was diagnosed in 73.2% ( = 30) of these cases. The PH-ILD Detection tool has a sensitivity of 93.3%, specificity of 90.9%, and area-under-the-curve of 0.921 for diagnosing PH in ILD patients, validating the findings from the original study and establishing the tool as a fundamental resource for early recognition of PH in ILD patients.

摘要

肺动脉高压(PH)会导致间质性肺疾病(ILD)患者的发病率和死亡率升高。在这一人群中早期识别PH对于规划诊断测试、启动治疗以及评估肺移植至关重要。先前开发的PH-ILD检测工具在ILD患者的评估和治疗中具有巨大潜力;本研究的目的是在一个独立的多中心患者队列中验证该工具。我们对前瞻性收集的161例ILD患者的数据进行了回顾性分析。根据该工具获得的评分,将患者分为低风险组(n = 78,48.4%)、中风险组(n = 54,33.5%)和高风险组(n = 29,18.0%)。中风险和高风险患者接受了随访超声心动图(TTE)检查;49.4%(n = 41)的患者TTE异常,提示存在潜在的PH。这些患者接受了右心导管检查;其中73.2%(n = 30)的病例被诊断为PH-ILD。PH-ILD检测工具在诊断ILD患者的PH方面,敏感性为93.3%,特异性为90.9%,曲线下面积为0.921,验证了原始研究的结果,并将该工具确立为早期识别ILD患者PH的重要资源。

相似文献

1
The PH-ILD Detection tool: External validation and use in patients with ILD.PH-ILD检测工具:外部验证及在ILD患者中的应用
Pulm Circ. 2023 Aug 8;13(3):e12273. doi: 10.1002/pul2.12273. eCollection 2023 Jul.
2
Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.间质性肺疾病患者的肺动脉高压:一种早期检测工具。
Pulm Circ. 2022 Oct 1;12(4):e12141. doi: 10.1002/pul2.12141. eCollection 2022 Oct.
3
The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.特发性肺纤维化相关 3 型肺动脉高压的困境:诊断中的两难处境与治疗中的难题。
Chest. 2020 Oct;158(4):1651-1664. doi: 10.1016/j.chest.2020.04.046. Epub 2020 May 7.
4
Clinical assessment for pulmonary hypertension in interstitial lung disease.特发性肺纤维化相关肺动脉高压的临床评估。
Intern Med J. 2023 Aug;53(8):1415-1422. doi: 10.1111/imj.15887. Epub 2022 Aug 3.
5
Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.特发性肺纤维化相关肺动脉高压:超声心动图与心导管检查的比较局限性。
Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.
6
Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.间质性肺疾病患者肺动脉高压的筛查策略:一项多学科德尔菲研究
Chest. 2022 Jul;162(1):145-155. doi: 10.1016/j.chest.2022.02.012. Epub 2022 Feb 15.
7
Noninvasive determinants of pulmonary hypertension in interstitial lung disease.间质性肺疾病中肺动脉高压的无创性决定因素
Pulm Circ. 2023 Feb 19;13(1):e12197. doi: 10.1002/pul2.12197. eCollection 2023 Jan.
8
Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension.间质性肺疾病相关肺动脉高压患者的死亡预测因素
J Clin Med. 2020 Nov 26;9(12):3828. doi: 10.3390/jcm9123828.
9
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压与系统性硬化症相关肺动脉高压患者治疗后血流动力学反应及结局比较:特发性肺纤维化相关肺动脉高压预后因素研究数据。
Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.
10
Efficacy and determinants of response to inhaled treprostinil in pulmonary hypertension - interstitial lung disease.吸入性曲前列尼尔治疗肺动脉高压-间质性肺病的疗效和反应决定因素。
Respir Med. 2024 Nov-Dec;234:107835. doi: 10.1016/j.rmed.2024.107835. Epub 2024 Oct 18.

引用本文的文献

1
Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection.PHINDER研究的设计与原理:对间质性肺疾病患者进行肺动脉高压筛查以实现早期诊断
Pulm Ther. 2025 Jul 25. doi: 10.1007/s41030-025-00307-0.
2
Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease.FORD模型与其他可用模型在间质性肺疾病患者肺动脉高压无创预测中的性能比较
Lung. 2025 Jan 22;203(1):27. doi: 10.1007/s00408-024-00783-2.
3
Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.汇聚途径:间质性肺疾病中的肺动脉高压综述
Life (Basel). 2024 Sep 23;14(9):1203. doi: 10.3390/life14091203.
4
Pulmonary hypertension associated with lung diseases.与肺部疾病相关的肺动脉高压。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01200-2024. Print 2024 Oct.
5
High Prevalence of Myositis-Specific and Associated Antibodies in Patients with Pulmonary Hypertension.肺动脉高压患者中肌炎特异性抗体和相关抗体的高患病率。
Diagnostics (Basel). 2024 Jul 9;14(14):1471. doi: 10.3390/diagnostics14141471.
6
Severe pulmonary hypertension-interstitial lung disease presenting as right ventricular failure: stabilisation with intravenous prostacyclin and maintenance with inhaled prostacyclin.以右心室衰竭为表现的重度肺动脉高压-间质性肺疾病:静脉注射前列环素实现病情稳定,吸入前列环素维持治疗
ERJ Open Res. 2024 Jan 29;10(1). doi: 10.1183/23120541.00659-2023. eCollection 2024 Jan.

本文引用的文献

1
Noninvasive determinants of pulmonary hypertension in interstitial lung disease.间质性肺疾病中肺动脉高压的无创性决定因素
Pulm Circ. 2023 Feb 19;13(1):e12197. doi: 10.1002/pul2.12197. eCollection 2023 Jan.
2
Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection.间质性肺疾病患者的肺动脉高压:一种早期检测工具。
Pulm Circ. 2022 Oct 1;12(4):e12141. doi: 10.1002/pul2.12141. eCollection 2022 Oct.
3
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
4
Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.间质性肺疾病患者肺动脉高压的筛查策略:一项多学科德尔菲研究
Chest. 2022 Jul;162(1):145-155. doi: 10.1016/j.chest.2022.02.012. Epub 2022 Feb 15.
5
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压患者应用吸入曲前列尼尔治疗
N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13.
6
Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights.肺纤维化继发肺动脉高压:临床数据、组织病理学和分子研究进展。
Respir Res. 2020 Nov 18;21(1):303. doi: 10.1186/s12931-020-01570-2.
7
Virtual echocardiography screening tool to differentiate hemodynamic profiles in pulmonary hypertension.用于区分肺动脉高压血流动力学特征的虚拟超声心动图筛查工具。
Pulm Circ. 2020 Sep 17;10(3):2045894020950225. doi: 10.1177/2045894020950225. eCollection 2020 Jul-Sep.
8
Risk assessment in severe pulmonary hypertension due to interstitial lung disease.特发性肺纤维化相关重度肺动脉高压的风险评估。
J Heart Lung Transplant. 2020 Oct;39(10):1118-1125. doi: 10.1016/j.healun.2020.06.014. Epub 2020 Jun 25.
9
The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment.特发性肺纤维化相关 3 型肺动脉高压的困境:诊断中的两难处境与治疗中的难题。
Chest. 2020 Oct;158(4):1651-1664. doi: 10.1016/j.chest.2020.04.046. Epub 2020 May 7.
10
Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?新的评分系统能否提高新发间质性肺疾病中肺动脉高压的预测能力?
Lung. 2020 Jun;198(3):547-554. doi: 10.1007/s00408-020-00346-1. Epub 2020 Mar 23.